Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology
Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company's BioJet platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine.
正在重新構想治療給藥的生物技術公司Biora Therapeutics, Inc.（納斯達克股票代碼：BIOR）今天宣佈發佈一項與該公司用於口服、全身輸送生物療法的BioJet平台有關的新專利，該平台使用一種可吸收的設備，旨在通過液體噴射輸送到小腸來實現全身吸收。
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,938,295 entitled, "Ingestible Device for Delivery of Therapeutic Agent to the Gastrointestinal Tract." The issued claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal (GI) tract, including the stomach or small intestine.
美國專利商標局（USPTO）已頒發了第11,938,295號美國專利，題爲 “向胃腸道輸送治療劑的可攝入裝置”。發佈的索賠涵蓋了液體噴射向胃腸道（GI）（包括胃或小腸）輸送藥物的關鍵噴射參數。
"This latest patent further secures Biora's broad and comprehensive ownership of liquid jet delivery to the GI tract. The BioJet platform's liquid jet injection technology, with systemic bioavailability and consistency shown to be comparable to traditional subcutaneous injection, is outperforming our performance targets in preclinical testing," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "Our approach also allows for the delivery of multi-milligram doses of nearly any liquid drug, with minimal to no reformulation. The BioJet platform's potential to deliver large molecules, including GLP-1 agonists, monoclonal antibodies, antisense oligonucleotides, and many others, and to achieve liver-targeted delivery through the hepatic portal, could transform oral delivery of therapeutics," stated Mr. Mohanty.
“這項最新專利進一步確保了Biora對向胃腸道輸送液體噴射的廣泛而全面的所有權。Biora Therapeutics首席執行官阿迪·莫漢蒂說，BioJet平台的液體噴射注射技術已證明其全身生物利用度和一致性與傳統皮下注射相當，其表現超過了我們在臨床前測試中的性能目標。“我們的方法還允許輸送幾乎所有液體藥物的數毫克劑量，幾乎無需重新配方。BioJet平台有可能提供大分子，包括 GLP-1 激動劑、單克隆抗體、反義寡核苷酸等，並有可能通過肝門實現肝臟靶向輸送，這可能會改變治療藥物的口服給藥，” 莫漢蒂說。
Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 12 issued patents and 31 pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs. These patents are part of Biora's larger corporate portfolio consisting of 73 patent families, including approximately 190 issued patents and 136 pending applications in major jurisdictions around the world, including the US, Europe, Canada, China, Japan, South Korea, Israel, Australia and Mexico.
Biora擁有BioJet系統性口服給藥平台的全面專利地位，約有12項已頒發的專利和31項待批申請，涵蓋了其交付平台以及使用該平台使用液體噴射輸送各種藥物治療患者疾病或病症的方法。這些專利是Biora由73個專利家族組成的更大企業組合的一部分，包括在美國、歐洲、加拿大、中國、日本、韓國、以色列、澳大利亞和墨西哥等全球主要司法管轄區的大約190項已頒發的專利和136項待處理的申請。
譯文內容由第三人軟體翻譯。